IDH1 and IDH2 Mutation Analysis, exon 4
Ordering Recommendation

Detect IDH1 and IDH2 mutations in whole blood or bone marrow. May have prognostic significance in patients with hematologic malignancies, depending on the clinical and genetic context. For FFPE tissues, use IDH1 and IDH2 Mutation Analysis, Exon 4, Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue (2014188).

Polymerase Chain Reaction/Sequencing
Sunday, Tuesday, Thursday
12-14 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Lavender (EDTA) OR bone marrow (EDTA) OR tumor tissue. 
Specimen Preparation
Whole blood: Transport 5 mL (Min: 1 mL) OR Bone marrow: Transport 3 mL (Min: 1 mL) OR FFPE tumor tissue: Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 4 unstained 5-micron thick slides (Min: 3 slides). Transport block and/or slid (s) in a tissue transport kit (ARUP supply # 47808) available online through eSupply using ARUP Connect™or contact ARUP Client Services at (800)522-2787. 
Storage/Transport Temperature
Whole blood OR Bone marrow: Refrigerated. FFPE tumor tissue: Room temperature or refrigerated. Ship in cooled containers during summer months. 
Unacceptable Conditions
Whole blood OR Bone marrow: Serum or plasma. Specimens collected in anticoagulants other than EDTA. Frozen specimens. Clotted or grossly hemolyzed specimens. FFPE tumor tissue: No tumor in tissue. Specimens fixed/processed in alternative fixatives (alcohol, Prefer®) or heavy metal fixatives (B-4 or B-5). Decalcified specimens. 
For FFPE specimens include surgical pathology report. Tissue block will be returned after testing. 
Ambient: 24 hours; Refrigerated: 5 days; Frozen: Unacceptable
FFPE tumor tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

CPT Code(s)
81403 x2; FFPE tumor tissue, add 88381
Component Test Code*Component Chart NameLOINC
2006445IDH1 and IDH2 Mutation Results35474-6
2006510IDH 1-2 Source31208-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • IDH1
  • IDH1 SNP
  • IDH2
  • Isocitrate dehydrogenase (IDH) 1 and 2
  • Isocitrate Dehydrogenase 1
  • Isocitrate Dehydrogenase 2
  • NADP+